Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27395795 | 0.97 | HTT (0.40) | HTTALDH1A1CYP1A2SMN1; SMN2SIGMAR1 | |
| SCHEMBL24828142 | 0.97 | ALDH1A1 (0.45) | HTTALDH1A1CYP1A2SMN1; SMN2SIGMAR1 | |
| SCHEMBL21038251 | 0.95 | ALDH1A1 (0.43) | HTTALDH1A1CYP1A2SMN1; SMN2SIGMAR1 | |
| SCHEMBL13547365 | 0.95 | HTT (0.39) | HTTALDH1A1CYP1A2SMN1; SMN2SIGMAR1 | |
| SCHEMBL18638609 | 0.93 | ALDH1A1 (0.41) | HTTALDH1A1CYP1A2SIGMAR1GNAI3 | |
| SCHEMBL25707964 | 0.93 | ALDH1A1 (0.41) | HTTALDH1A1CYP1A2SIGMAR1GNAI3 | |
| SCHEMBL21535942 | 0.92 | SMN1; SMN2 (0.35) | HTTALDH1A1CYP1A2SMN1; SMN2SIGMAR1 | |
| SCHEMBL12642 | 0.87 | — | — | |
| SCHEMBL13547364 | 0.87 | — | — | |
| SCHEMBL10279384 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021158829-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | Stingray Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-8394955-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR0B1, NR1H3, NCOA3 | HTT 1916/4885ALDH1A1 1457/4885CYP1A2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.